EUVIMEDEUVIMED entdecken
Crossref

Cardiovascular Prevention and the Implementation Gap in GLP-1 Receptor Agonist Therapies

John Erhabor, Nader Silver, Michael J Blaha

JACC · 2026-08 · 88 (6) · 710-712

DOI: 10.1016/j.jacc.2026.06.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC, 2026-08. Verfasst von John Erhabor und 2 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. E…. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 receptor agonistcardiovascular preventionimplementation

Autor:innen und Institutionen

  • Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: john.erhabor@sgmc.org.
  • Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Zitieren

APA

Erhabor, J., Silver, N., & Blaha, M. J. (2026). Cardiovascular Prevention and the Implementation Gap in GLP-1 Receptor Agonist Therapies. JACC, 88(6), 710-712. https://doi.org/10.1016/j.jacc.2026.06.024

Vancouver

Erhabor J, Silver N, Blaha MJ. Cardiovascular Prevention and the Implementation Gap in GLP-1 Receptor Agonist Therapies. JACC. 2026;88(6):710-712. doi:10.1016/j.jacc.2026.06.024

BibTeX
@article{Erhabor2026,
  author = {Erhabor, John and Silver, Nader and Blaha, Michael J},
  title = {Cardiovascular Prevention and the Implementation Gap in GLP-1 Receptor Agonist Therapies},
  journal = {JACC},
  year = {2026},
  volume = {88},
  number = {6},
  pages = {710--712},
  doi = {10.1016/j.jacc.2026.06.024}
}
Kostenlos starten →